HemaCare Corporation Stock

HEMA

US4234981045

Healthcare Facilities & Services

Delayed OTC Markets			5-day change	1st Jan Change
- ^USD	-.--%		+0.08%	+0.24%

20-06-02	HemaCare Corporation Adds GMPrime Cryopreserved Leukopak to its GMP Product Portfolio	CI
20-01-21	MicroMedicine and HemaCare Announces Cooperative Efforts to Improve Cell Therapy Starting Materials	CI

Valuation: HemaCare Corporation

Market Cap	346M 296M 277M 253M 478M 33.1B 483M 3.28B 1.28B 16.62B 1.3B 1.27B 55B	P/E 2017	8.18x	P/E 2018	27.6x
Enterprise Value	336M 288M 269M 246M 464M 32.15B 469M 3.19B 1.24B 16.15B 1.26B 1.23B 53.42B	EV / Sales 2017	1.29x	EV / Sales 2018	4.03x
Free-Float	94.17%	Yield 2017 *	-	Yield 2018	-

* Estimated data More valuation ratios

Latest news : HemaCare Corporation

20-06-02	HemaCare Corporation Adds GMPrime Cryopreserved Leukopak to its GMP Product Portfolio	CI
20-01-21	MicroMedicine and HemaCare Announces Cooperative Efforts to Improve Cell Therapy Starting Materials	CI
20-01-02	Charles River Laboratories International, Inc. completed the acquisition of HemaCare Corporation.	CI
19-12-15	Charles River Laboratories International, Inc. entered into a definitive agreement to acquire HemaCare Corporation for approximately $380 million.	CI
19-11-19	HemaCare Expands Its Product Portfolio with GMPrime™ Bone Marrow Aspirate	CI
19-08-27	HemaCare Corporation and Vital River Partner to Provide Human-Derived Biological Material to China	CI
19-08-20	Hemacare Corporation Reports Earnings Results for the Half Year Ended June 30, 2019	CI
19-03-26	HemaCare Corporation Reports Earnings Results for the Year Ended December 31, 2018	CI
18-12-19	HemaCare Corporation announced that it has received $4.999999 million in funding from OBF Investments LLP	CI
18-12-06	HemaCare Corporation Moves its Global Headquarters to Northridge, California	CI
18-11-14	HemaCare Corporation Provides Starting Material for Three FDA Approved Cellular Therapies	CI
18-08-21	HemaCare Corporation Reports Unaudited Earnings Results for the Six Months Ended June 30, 2018	CI
18-07-17	HemaCare Corporation Announces Executive Appointments	CI

More news

Press Releases: HemaCare Corporation

19-12-16

HEMACARE ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of HEMA and Encourages Investors to Contact the Firm

More press releases

Managers and Directors: HemaCare Corporation

Manager	Title	Age	Since
Colin S. Dunn CEO	Chief Executive Officer	-	-
Samira Amini DFI	Director of Finance/CFO	-	-
Maria Pia Muniz COO	Chief Operating Officer	-	2002-12-31

Director	Title	Age	Since
Colin S. Dunn BRD	Director/Board Member	-	-
Samira Amini BRD	Director/Board Member	-	-
Emily Nekimken BRD	Director/Board Member	-	-

More insiders

Other Healthcare Facilities & Services

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
HEMACARE CORPORATION	-.--%	+0.08%	-	-	346M
CVS HEALTH CORPORATION	+1.17%	+0.11%	+31.99%	+41.54%	119B
HCA HEALTHCARE, INC.	+0.01%	+5.99%	+5.99%	+57.47%	92.92B
FRESENIUS SE & CO. KGAA	-1.20%	-1.49%	-3.46%	+57.13%	30.64B
QUEST DIAGNOSTICS INCORPORATED	-0.21%	+3.55%	+35.31%	+83.06%	26.97B
TENET HEALTHCARE CORPORATION	-0.78%	+5.30%	+55.20%	+277.14%	22.61B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	-0.17%	+3.03%	-3.95%	-6.67%	22.22B
REDE D'OR SÃO LUIZ S.A.	+0.79%	+4.32%	-8.60%	+16.39%	14.47B
FRESENIUS MEDICAL CARE AG	+0.40%	-1.20%	-7.57%	-9.50%	12.42B
DAVITA INC.	+1.54%	-0.11%	+25.75%	+74.67%	11.08B
Average	+0.16%	+1.74%	+14.52%	+65.69%	35.27B
Weighted average by Cap.	+0.31%	+2.34%	+18.27%	+60.56%

See all sector performances

Charles River Laboratories Cell Solutions, Inc. is a cell sourcing provider for developers of cell therapies and basic research. The Company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. It offers a comprehensive and integrated portfolio of drug development products and services available from a single global provider, spanning the continuum from early research to the support of marketed products. Its products and services include Research Models & Services, Discovery Services Safety Assessment, Laboratory Sciences, Cell and Gene Therapy CDMO Solutions, Biologics Testing Solutions, Avian Vaccine Services, QC Microbial Solutions, Scientific & Regulatory Advisory Services, and Scientific Staffing, Training & Operations Support.

Employees

Sector

Healthcare Facilities & Services

More about the company

Stock Market
Stocks
HEMA Stock

As early as today, start finding the best investment opportunities!

Maximize my profits

	2017	2018
Net sales	20.21M 17.32M 16.2M 14.81M 27.96M 1.94B 28.25M 192M 74.56M 972M 75.89M 74.25M 3.22B	28.51M 24.43M 22.85M 20.89M 39.43M 2.73B 39.85M 270M 105M 1.37B 107M 105M 4.53B
Net income	4.43M 3.8M 3.55M 3.25M 6.13M 424M 6.2M 42.05M 16.35M 213M 16.64M 16.28M 705M	4.52M 3.87M 3.62M 3.31M 6.25M 432M 6.31M 42.84M 16.66M 217M 16.96M 16.59M 718M
Net Debt	-9.06M -7.76M -7.26M -6.64M -12.53M -867M -12.66M -85.94M -33.42M -436M -34.01M -33.28M -1.44B	-9.9M -8.48M -7.93M -7.25M -13.69M -948M -13.84M -93.89M -36.51M -476M -37.16M -36.36M -1.57B

HemaCare Corporation Stock

Stocks

HEMA

US4234981045

Healthcare Facilities & Services

Valuation: HemaCare Corporation

Latest news : HemaCare Corporation

Press Releases: HemaCare Corporation

Managers and Directors: HemaCare Corporation

Other Healthcare Facilities & Services

Financials

Company Profile